Hyperion Therapeutics, Inc. (Nasdaq: HPTX ) today announced that the U.S. Food and Drug Administration (FDA) has approved RAVICTI for the treatment of Urea Cycle Disorders (UCD) in patients two years of age and older. The drug is expected to be commercially available by the end of April 2013. Separately, Hyperion announced it